We treated with NRASmut transformed Ba/F3 cells with DNR and found that NRASG12D ALL cells were more resistant to DNR than those with wild-type NRAS (IC50: 57.4 vs. 5.8 nM) (Figure 2D), which was in line with previous reports (Irving et al., 2014; Irving et al., 2016). Here, NRAS is linked to acute lymphoblastic leukemia.